Aspo to divest Leipurin business to Lantmännen for EUR 63 million.

Aspo Plc is divesting its Leipurin business to Lantmännen for an enterprise value of EUR 63 million. The transaction is expected to complete in Q1 2026 and will strengthen Aspo's balance sheet, enabling future growth investments for the Telko business. This move is part of Aspo's portfolio vision to form two separate companies and maximize shareholder value.

Aspo Plc has announced its intention to divest its Leipurin business to Lantmännen, a significant move that aims to strengthen Aspo's balance sheet and enable future growth investments for its Telko business. The transaction, valued at an enterprise value of EUR 63 million, is subject to regulatory approvals and is expected to be completed in the first quarter of 2026.

The divestment of Leipurin is a key step in Aspo's portfolio vision to form two separate companies, Aspo Compounder (Telko and Leipurin) and Aspo Infra (ESL Shipping). This strategic move is part of Aspo's broader effort to maximize shareholder value. Rolf Jansson, CEO of Aspo Plc, stated, "The divestment of Leipurin is the best way to implement Aspo’s strategy and value creation. During the past years, Leipurin has sold its equipment-related businesses, exited its businesses in the east and completed three acquisitions in western markets. We have also clearly improved the performance of Leipurin in recent years and supported the success of our customers."

The Leipurin business, which offers food ingredients and expert services in the bakery, food industry, and food service markets in Finland, Sweden, and the Baltic countries, will operate as a separate business within Lantmännen's Energy Division. The acquisition aligns with Lantmännen's strategy to broaden and strengthen its value chain in food ingredients. Magnus Kagevik, President and CEO of Lantmännen, commented, "Together with our existing operations and the new plant-based protein facility currently under construction, we see strong opportunities for growth in both existing and new markets. With Leipurin, we gain valuable expertise in developing innovative products in close collaboration with customers."

The divestment of Leipurin will have a significant impact on Aspo's financials. Upon completion, Aspo will record a sales gain of approximately EUR 16 million, which will impact its reported result. The transaction does not affect Aspo's guidance for 2025, with Aspo Group's comparable EBITA expected to be EUR 35–45 million. The sale of the Leipurin business will be implemented as a sale of shares, covering all the companies in the Leipurin segment.

Lantmännen, an agricultural cooperative and Northern Europe's leader in agriculture, machinery, bioenergy, and food products, is owned by 17,000 Swedish farmers and has 12,000 employees and operations in over 20 countries. The annual turnover of Lantmännen is SEK 70 billion.

For additional information, please contact Rolf Jansson, CEO of Aspo Plc, at tel. +358 400 600 264, rolf.jansson@aspo.com.

References:
[1] https://finance.yahoo.com/news/inside-information-aspo-divest-leipurin-083000986.html